|
Prescription Drug Search
Product Request Form
Alemtuzumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Alemtuzumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about CancerDrugsDirect.com
List of countries where we can ship Alemtuzumab:
- Argentina
- Armenia
- Australia
- Azerbaijan
- Bahamas
- Bangladesh
- Belize
- Bolivia
- Cayman Islands
- Croatia
- Cuba
- Cyprus
- Finland
- France
- Georgia
- Greenland
- Hong Kong
- Iceland
- India
- Iraq
- Italy
- Japan
- Korea, South
- Morocco
- Nicaragua
- Norway
- Philippines
- Singapore
- Slovakia
- Switzerland
- Taiwan
- Thailand
- Tunisia
- Turkey
- Ukraine
- United Arab Emirates
- United Kingdom, UK
- United States, US
- Venezuela
- Vietnam
Latest news releases on Alemtuzumab:
Alemtuzumab Heads for Regulatory Review in MS - Medscape News
May 7, 2012 (New Orleans, Louisiana) — Full results of a second phase 3 trial of alemtuzumab (Lemtrada, Genzyme/Sanofi) in patients with relapsing-remitting multiple sclerosis (MS) who had relapsed while receiving previous treatment show that the still ...
Significant Improvement In Disability Scores With Alemtuzumab - Medical News Today
Genzyme presented additional data at the 64th Annual Meeting of the American Academy of Neurology from its Phase II CARE-MS II trial, which demonstrated that the Expanded Disability Status Scale (EDSS), i.e. a standard assessment of physical ...
Genzyme says Lemtrada improves disability scores in multiple sclerosis patients - pharmabiz.com
Accumulation of disability was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif (high dose subcutaneous interferon beta-1a), as measured by the Expanded Disability Status Scale (EDSS), a standard ...
Sanofi's Genzyme (SNY) to Present Data from MS Trials Using Alemtuzumab and Teriflunomide - StreetInsider.com
Genzyme, a Sanofi company (NYSE: SNY), announced that 12 data presentations, including six platform presentations, from the company’s multiple sclerosis (MS) clinical trial programs for alemtuzumab and teriflunomide will be featured at the American ...
The aplastic anemia market is forecast to show slow growth until 2019 - Transworld News
There is no molecule in Phase III of development. The only molecule in Phase II/III is alemtuzumab. Alemtuzumab is under investigation as a conditioning regimen for patients with severe aplastic anemia who are undergoing allogeneic stem cell ...
Two New Promising Treatments for MS - WTVQ
One of the drugs on the horizon is a yearly IV infusion called Alemtuzumab. This drug was studied in over 800 patients with relapsing MS, and results show that it is more effective in treating this type of MS than standard 3-times per week injections of ...
Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.
Passing of Genmab A/S' Annual General Meeting - TradersHuddle.com
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 - finanztreff
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...
